Health Care/Hospital
CBC Group-backed Hasten Biopharma successfully completes acquisition of five cardiovascular and metabolism drugs from Takeda
* CBC Group continues to expand its global healthcare ecosystem to fulfil unmet medical needs * Hasten fast-tracks transformative medicines for patients in China SHANGHAI, March 31, 2022 /PRNewswire/ -- Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired a ...
2022-03-31 15:05
1708
LifeTech Scientific Corporation（1302.HK） Announces 2021 Annual Results
Excluding certain non-recurring items, the net profit attributable to owners of the Company increased by 76.8% to RMB 324.0million SHENZHEN, China, March 30, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (LifeTech, 1302.HK), a leading company specialized in minimally invasive interventio...
2022-03-31 03:27
3022
Keymed Biosciences Releases 2021 Annual Results
CHENGDU, China, March 30, 2022 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX Code: 02162) released 2021 annual results. BUSINESS HIGHLIGHTS On July 8, 2021, Keymed was listed on the HKEX. During the Reporting Period, the Company continued proceeding the R&D of products and made the following p...
2022-03-30 23:41
2374
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights
SUZHOU, China, March 29, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2021 and highlighted recent progress and upcoming milestones. Highlights * First product launch: In November 2021, KN035 (Envafolimab) has receiv...
2022-03-30 10:35
1907
Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology
- Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody - Biosion earns a $10 million upfront license fee; additional milestone payments and royalties on commercial sales to be earned up...
2022-03-29 23:00
1832
MedTech Baymatob completes capital raise to advance life-saving labor monitoring device
SYDNEY, March 29, 2022 /PRNewswire/ -- Medical device company Baymatob has completed a placement ofA$4.215 million, with proceeds used to continue in-human clinical trials for its AI-guided labor monitoring device, Oli. Cornerstoned by Australian Unity's Future of Healthcare Fund, the placement ...
2022-03-29 21:34
1707
CellOrigin Closed a New Round of Investment to Jump-start its iPSC Immune Cell Therapy Products Toward Clinics
HANGZHOU, China, March 29, 2022 /PRNewswire/ -- On Mar.21, 2022, CellOrigin Inc, a biotech company focusing on iPSC-derived immune cell therapies, announced it secured a new round of investment of ~100 million RMB from Jifeng Ventures, Kunlun Capital, Yinxinggu Capital and Efung Capital. CellOri...
2022-03-29 20:50
1422
Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care
AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the signing of an exclusive global supply and licensing agreement with Heska Corporation (NASDAQ: HSKA) ("Heska") to sell its Nu.Q® Vet Cancer ...
2022-03-29 20:00
2029
Laekna Therapeutics Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board
SHANGHAI and WARREN, N.J., March 29, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage global biotechnology company，announced today the appointment of Jeff Porter, Ph.D. as the Chairman of its Scientific Advisory Board (SAB). Dr. Porter has over 25 years of global R&D leadership and strat...
2022-03-29 20:00
1453
New Video Series "PSMA PET/CT TODAY" Discusses the Future of Prostate Cancer Care with Leading Experts
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the launch of PSMA PET/CT[1] Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in pr...
2022-03-29 19:00
1356
Leading brand of mosquito repellent for children in the UK Gurkha Protec launches combo package
The British brand that has specialized in mosquito repellent for 40 years is now available! With 40 years dedication and products sold worldwide, Gurkha Protec is launching a two-color combination package BEIJING, March 29, 2022 /PRNewswire/ -- Gurkha Protec was founded in 1981. We have been ...
2022-03-29 18:12
1493
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
* Financial results demonstrate strong fundamentals * Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab and felzartamab * Seven business development deals, including a US$315M strategic commercial partnership with Jumpcan on...
2022-03-29 18:10
2689
Nippon Express (Middle East) Becomes First Japanese Logistics Company to Acquire GDP Certification in Middle East
TOKYO, March 29, 2022 /PRNewswire/ -- Nippon Express (Middle East) L.L.C. (hereinafter "NX Middle East"), a group company of Nippon Express Holdings, Inc., onFebruary 3, 2022, became the first Japanese logistics company in the Middle East to obtain Good Distribution Practice (GDP) certification f...
2022-03-29 14:00
1337
Samsung Biologics holds 11th Annual General Meeting of Shareholders
INCHEON, South Korea, March 28, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), hosted its 11th Annual General Meeting of Shareholders (AGM)today. Five matters were presented and approved unanimously at this ...
2022-03-29 09:42
1927
VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update
Conference call to take place on Thursday March 31 at 08:00a.m. Eastern time AUSTIN, Texas, March 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday March 31, 08.00a.m. Eastern time to discuss its financial and ...
2022-03-29 04:25
1982
Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%
Financial Highlights of the year ended December 31, 2021: * Revenue amounted to RMB2,104.1 million, representing a year-on-year (YoY) increase of 201.9% * Gross profit amounted to RMB651.0 million, representing a YoY increase of 113.5% * Adjusted Non-IFRS net profit amounted to RMB352.5 mil...
2022-03-29 00:49
2489
Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment
SYDNEY, March 28, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT05249127 <...
2022-03-28 21:06
1742
First-ever integrated EEG and neurotherapeutics device iSyncWave wins the 2022 Red Dot Design Award
SEOUL, South Korea, March 28, 2022 /PRNewswire/ -- AI-based digital mental
healthcare platform company iMediSync has announced that their product
"iSyncWave" has won the 2022 Red Dot Design Award for its innovative and
creative design asa dry EEG headset.
2022-03-28 20:00
1608
Tigermed Reports Strong 2021 Full-Year Results
HANGZHOU, China, March 28, 2022 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its an...
2022-03-28 19:10
2313
At the 2022 AAD Annual Meeting, Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma
* Early results showed 2 laBCC (locally advanced Basal Cell Carcinoma) subjects out of 10 experienced a Partial Response (30% decrease in tumor size) at week #24. * The first biopsy analysis in the laBCC subject showed a more than 90% decrease of GLI-1 expression at week #8 (GLl-1 is involved...
2022-03-28 19:00
1495
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 301 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00TAILG's First Flagship Store in Indonesia Grandly Opens
[Picked up by 283 media titles]
2024-11-22 21:59
MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
11004
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
7041
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
6966
